Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Comparison of Three-dimensional and Two-dimensional Left Ventricle Strain With Speckle-tracking Echocardiography in Heart Failure With Reduced and Mildly Reduced Ejection Fraction (3V2-STEM-HF)

18 de agosto de 2026 actualizado por: Istituti Clinici Scientifici Maugeri SpA

Left Ventricular Myocardial Strain Assessed by Three-dimensional Speckle-tracking Echocardiography in Heart Failure With Reduced and Mildly Reduced Ejection Fraction. A Comparison With Two-dimensional Evaluation in a Prospective Study

This study will compare two ultrasound techniques, 2D and 3D speckle-tracking echocardiography, for measuring how well the heart muscle contracts in patients with heart failure and reduced pumping function. While 2D global longitudinal strain (GLS) is widely used and has proven value in predicting outcomes, 3D GLS may provide a more complete assessment of heart function. Researchers will enroll 419 patients from seven cardiac rehabilitation hospitals in Italy and analyze heart ultrasound images using standardized equipment and software. The study will assess how closely 2D and 3D GLS measurements agree, identify factors that influence any differences, and determine whether 3D GLS better predicts the risk of death than 2D GLS.

Descripción general del estudio

Estado

Reclutamiento

Descripción detallada

Left Ventricular Myocardial Strain Assessed by Three-Dimensional Speckle-Tracking Echocardiography in Heart Failure with Reduced or Mildly Reduced Ejection Fraction: Comparison with Two-Dimensional Assessment in a Prospective Observational Study

Background

Global longitudinal strain (GLS) derived from speckle-tracking echocardiography (STE) is a robust, well-validated, and reproducible technique for assessing left ventricular (LV) longitudinal deformation and is available on most modern echocardiography systems. GLS appears to provide superior prognostic value compared with ejection fraction (EF) for predicting major adverse cardiac events across various clinical settings, including chronic heart failure (CHF).

Three-dimensional (3D) STE represents a further advancement in myocardial deformation imaging, enabling rapid and comprehensive assessment of all LV segments and measurement of global 3D GLS from a single dataset. However, in healthy individuals, reference values for 3D and 2D GLS differ significantly, likely because 3D GLS more accurately captures the complex mechanics of LV contraction, whereas 2D GLS provides higher spatial and temporal resolution.

Although 3D STE is increasingly being used to evaluate LV systolic function in patients with CHF, data regarding the agreement and differences between 2D and 3D measurements in this clinical setting remain limited. This issue is particularly relevant in patients with systolic heart failure, as reduced EF appears to weaken the correlation between 2D and 3D GLS measurements, according to available studies with relatively small sample sizes.

Objectives

This prospective multicenter study aims to evaluate the agreement between 2D and 3D GLS measurements obtained using single-vendor ultrasound systems and analysis software in patients with heart failure with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF).

Secondary objectives are to identify factors associated with differences between 2D and 3D GLS measurements and to determine whether 3D GLS is a stronger independent predictor of all-cause mortality than 2D GLS.

Methods Study Population

This multicenter prospective observational study will enroll patients with HFrEF and HFmrEF, defined as a left ventricular ejection fraction (LVEF) ≤40% and 41-49%, respectively, from the echocardiography laboratories of the Cardiovascular Department of Istituti Clinici Scientifici (ICS) Maugeri across seven tertiary cardiac rehabilitation hospitals in Italy.

The study protocol has been approved to the local Ethics Committee. Written informed consent will be obtained from all participants before eligibility screening.

Image Acquisition and Analysis

Echocardiographic datasets will be acquired using Vivid E95 ultrasound systems (GE Vingmed Ultrasound AS, Horten, Norway) equipped with M5S and 4V probes for 2D and 3D imaging, respectively, or a 4VC probe for both 2D and 3D acquisitions.

The acquisition protocol will include 2-, 3-, and 4-chamber apical views, as well as parasternal short-axis views at the mid-papillary level for 2D imaging, together with 3D LV datasets for the assessment of myocardial strain parameters using 2D and 3D STE. If necessary, two- to six-beat full-volume 3D acquisitions will be performed to ensure complete LV coverage with a frame rate of at least 37 volumes/s.

Two-dimensional and three-dimensional datasets will be analyzed offline using the Q-Analysis and 4D AutoLVQ software packages (EchoPAC BT12 and BT13; GE Vingmed Ultrasound AS) by investigators with at least three years of experience.

Peak global 2D longitudinal strain (2DLε) will be calculated from the three apical views, whereas peak global 2D circumferential strain (2DCε) will be derived from the parasternal short-axis view. Three 3D strain parameters will be obtained from the 3D LV dataset: longitudinal strain (3DLε), circumferential strain (3DCε), radial strain (3DRε), and area strain (3DAε).

Datasets will be excluded from analysis under the following conditions:

  1. poor image quality of either the 2D or 3D datasets, defined using a 4-point scale (poor = 1, fair = 2, good = 3, excellent = 4) because of inadequate signal-to-noise ratio, poor blood-tissue contrast, stitching artifacts or incomplete visualization of the LV wall;
  2. inadequate tracking of more than two LV segments in a single apical 2D view for global 2DLε analysis or in the parasternal short-axis view for 2DCε and 2DRε analysis;
  3. inadequate tracking of more than three LV segments during 3D dataset analysis.

Sample Size

Agreement between 2D and 3D GLS measurements will be assessed using Bland-Altman analysis. Based on published data reporting a mean difference of 0.1% and a standard deviation of differences of 2.9%, the required sample size was calculated to be 419 participants, assuming a maximum acceptable difference between methods of ±6.5%, a type I error (α) of 5%, and a type II error (β) of 20%.

Statistical Analysis

Normally distributed continuous variables will be summarized as mean ± standard deviation (SD), whereas non-normally distributed continuous variables will be reported as median and interquartile range (IQR). Categorical variables will be expressed as counts and percentages.

All LV strain parameters will be analyzed as absolute values, with lower values indicating worse myocardial deformation and higher values indicating better deformation.

Differences between groups will be assessed using unpaired t-tests for normally distributed variables and Mann-Whitney U tests for non-normally distributed variables. Agreement between 2D and 3D LV strain measurements will be evaluated using Bland-Altman analysis. Differences between paired 2D and 3D strain measurements within predefined subgroups will be assessed using paired statistical tests, as appropriate.

Pearson correlation analysis will be used to evaluate associations between the differences in 2D and 3D GLS measurements and demographic, cardiac, and technical variables. Stepwise multivariable linear regression analysis will be performed to identify independent predictors of the differences between 2D and 3D GLS measurements, including age, sex, weight, height, blood pressure, body surface area (BSA), LV volumes, LV mass, temporal resolution, and 3D image quality.

The area under the receiver operating characteristic curve (AUC-ROC) will be used to assess the predictive performance of 2D and 3D GLS for all-cause mortality. The DeLong test will be used to compare the AUCs of the two methods.

All hypothesis tests will be two-sided, and a p-value <0.05 will be considered statistically significant. Statistical analyses will be performed using SPSS software (IBM, Armonk, NY, USA).

Tipo de estudio

De observación

Inscripción (Estimado)

419

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Veruno, Italia, 28013
        • Reclutamiento
        • ICS Maugeri - Istituto di Veruno
        • Contacto:
    • BA
      • Bari, BA, Italia, 70124
    • MI
      • Milan, MI, Italia, 20138
        • Reclutamiento
        • ICS Maugeri - Istituto di Milano
        • Contacto:
    • PV
      • Pavia, PV, Italia, 27100
        • Reclutamiento
        • ICS Maugeri - Istituto di Pavia
        • Contacto:
        • Contacto:
    • TO
      • Torino, TO, Italia, 10124
        • Reclutamiento
        • ICS Maugeri Torino
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Método de muestreo

Muestra no probabilística

Población de estudio

Patients with a diagnosis of heart failure and a reduced or mildly reduced ejection fration of left ventricle

Descripción

Inclusion Criteria:

  • Left ventricular ejection fraction (LVEF) ≤ 49%;
  • Echocardiographic image quality judged to be at least adequate according to a four-point visual image quality scale (good, adequate, poor, or inadequate)

Exclusion Criteria:

  • Inability to maintain the correct position for acquiring echocardiographic images;
  • Arrhythmias that make multi-beat acquisition impossible (if required), such as frequent extrasystoles (supraventricular or ventricular) and atrial fibrillation;
  • Failure to visualize more than 2 segments of the left ventricle (LV), or inability to assess more than 3 segments during 3D GLS analysis;
  • Failure to sign the informed consent form and inability of the participant to understand the objectives of the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
Heart failure with reduced ejection fraction (HFrEF) or mildly reduced ejection fraction (HFmrEF)
Patients with HFrEF or EFmrEF will be assessed with 2D and 3D echocardiography to evaluate the agreement between 2D and 3D global longitudinal strain measurements

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Bland-Altman mean difference (bias) and the limits of agreement (LOA) in comparison with a clinically acceptable range (±6.5%)
Periodo de tiempo: At baseline
Bias and the LOA will be compared with a clinically acceptable range (±6.5%)
At baseline

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Covariates and Confounders
Periodo de tiempo: At baseline
The factors associated with differences between 2D and 3D GLS measurements
At baseline
Comparison of all-cause mortality by 2D and 3D global longitudinal strain
Periodo de tiempo: From enrollment to the end of follow-up (1 year)
The area under the receiver operating characteristic curve (AUC-ROC) will be used to assess the predictive performance of 2D and 3D GLS for all-cause mortality. The DeLong test will be used to compare the AUCs of the two methods.
From enrollment to the end of follow-up (1 year)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

8 de enero de 2026

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

28 de julio de 2026

Primero enviado que cumplió con los criterios de control de calidad

28 de julio de 2026

Publicado por primera vez (Actual)

3 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

19 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

All data (anonymized)

Marco de tiempo para compartir IPD

Start date: 6 months after publication of the primary study results. End date: 5 years after publication of the primary study results.

Criterios de acceso compartido de IPD

De-identified individual participant data underlying the published results, together with the study protocol and statistical analysis plan, will be available to qualified researchers upon reasonable request to the principal investigator. Access will be granted following review and approval of a research proposal and completion of a data-sharing agreement. Data will be provided electronically in a secure manner

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir